The American College of Radiology (ACR) has issued a statement on the newly released Final USPSTF Breast Cancer Screening Recommendations

Getty Images


May 1, 2024 — The American College of Radiology (ACR) has issued a statement on the newly released Final USPSTF Breast Cancer Screening Recommendations. The final United States Preventive Services Task Force (USPSTF) Breast Cancer Screening Recommendations, while an improvement over previous guidance, do not go far enough to save more women’s lives.

The American College of Radiology will continue to urge the USPSTF to recommend all women have a breast cancer risk assessment by age 25 (as called for in ACR’s Breast Cancer Screening guidelines for high-risk women) and that women at average risk for breast cancer receive an annual mammography screening starting at age 40. Women at higher risk for breast cancer should talk to their doctor about starting screening prior to age 40 and additional screening methods.

The USPSTF, American College of Radiology, American Cancer Society, Society of Breast Imaging and others all agree that the most lives are saved with this annual approach. The ACR and SBI maintain their commitment to promote the value of annual screenings with mammography as stated in their joint average-risk guidelines. Medical experts must clear the confusion caused by differing recommendations.

Mounting evidence shows that Black and other minority women, Jewish women, and others develop and die from breast cancer prior to age 50 — or even age 40 — more often than white women. As our 2021 guidelines for average-risk women and our 2023 guidelines for high-risk women make clear, potentially giving cancer another year to advance may particularly impact these women.

Involving factors such as sex assigned at birth, hormone use and surgical history place transgender persons at increased risk for breast cancer. Biological females transitioning to male who do not undergo mastectomy remain at their previous risk for breast cancer and should continue to be screened as such. 

As outlined in current (2021) ACR/SBI recommendations for average-risk women, due to hormone use, biological males transitioning to female are at increased risk for breast cancer compared to other males and should speak with their doctor about their breast cancer risk.

ACR and SBI also recommend that women continue screening past age 74, unless severe comorbidities limit life expectancy. 

For more information: www.acr.org

Related content:

Leading Organizations and Breast Imaging Experts Weigh in on New Task Force Screening Recommendations, Impact on Health Equity and Women’s Health

Leading Organizations and Breast Imaging Experts Weigh in on New Task Force Screening Recommendations, Impact on Health Equity and Women’s Health


Related Content

News | Breast Imaging

June 18, 2024 — Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue Breast ...

Time June 18, 2024
arrow
News | Digital Radiography (DR)

June 12, 2024 — Carestream launched its Image Suite MR 10 Software to help deliver a boost to productivity and ...

Time June 12, 2024
arrow
News | MRI Breast

June 12, 2024 — Royal Philips recently announced the 1,111th installation of its revolutionary BlueSeal 1.5T magnet ...

Time June 12, 2024
arrow
News | Breast Imaging

June 7, 2024 — Scholars and studies funded by Susan G. Komen(R), the world’s leading breast cancer organization ...

Time June 07, 2024
arrow
News | Breast Density

June 6, 2024 — Subsequent rounds of abbreviated breast MRI (AB-MR) screening in patients with dense breasts had lower ...

Time June 06, 2024
arrow
News | Breast Imaging

June 4, 2024 — Using artificial intelligence (AI), breast radiologists in Denmark have improved breast cancer screening ...

Time June 04, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

As we flip the page to a new month on our calendars, here is a look at the Top 10 pieces of content viewers were reading ...

Time June 04, 2024
arrow
News | Breast Imaging

May 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced a ...

Time May 28, 2024
arrow
News | FDA

May 22, 2024 — The U.S. Food and Drug Administration (FDA) has issued a recall of the Hologic Inc. BioZorb marker due to ...

Time May 22, 2024
arrow
News | Artificial Intelligence

May 22, 2024 — Lunit, a provider of Artificial intelligence (AI)-powered solutions for cancer diagnostics and ...

Time May 22, 2024
arrow
Subscribe Now